Showing results (161-170 of 10,059) with videos related to
Sort By:
Pageof 1,006
Current Pharmaceutical Design|March 10, 2007
Invasion and egress by the obligate intracellular parasite Toxoplasma gondii: potential targets for the development of new antiparasitic drugsM D Lavine, G ArrizabalagaCurrent Pharmaceutical Design|March 10, 2007
Anti-apoptotic actions of insulin-like growth factors: lessons from development and implications in neoplastic cell transformationIsabel Varela-Nieto, Markus Hartl, Itziar Gorospe, et al.Current Pharmaceutical Design|March 14, 2007
Current concepts for the combined treatment modality of ionizing radiation with anticancer agentsChristoph Oehler, Daniel J Dickinson, Angela Broggini-Tenzer, et al.Current Pharmaceutical Design|October 6, 2006
Treatment of allergic asthma by targeting transcription factors using nucleic-acid based technologiesSerdar Sel, Wolfgang Henke, Alexander Dietrich, et al.Current Pharmaceutical Design|November 15, 2006
Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to their in vitro and in vivo antimicrobial activitiesHaruaki TomiokaCurrent Pharmaceutical Design|November 15, 2006
Enhancement of TLR-mediated innate immune responses by peptidoglycans through NOD signalingH Takada, A UeharaCurrent Pharmaceutical Design|November 15, 2006
TLR2 and TLR4 expression during bacterial infectionsE LorenzCurrent Pharmaceutical Design|November 15, 2006
Recognition of fungal pathogens by toll-like receptorsMihai G Netea, Gerben Ferwerda, Chantal A A van der Graaf, et al.Current Pharmaceutical Design|November 15, 2006
Toll-like receptor-positive cells and recognition of pathogens: how human myeloid dendritic cells respond to in vitro infection with Leishmania infantumMaria Pepe, Maria Altamura, Rosa Spinelli, et al.Current Pharmaceutical Design|December 16, 2006
Pro-oxidant milieu blunts scissors: insight into tumor progression, drug resistance, and novel druggable targetsShazib PervaizPageof 1,006